Clinical trials: Rituximab, completed
Chronic Lymphocytic Leukemia
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
The investigators' hypothesis is that treatment of CLL with an alternating daily dosing schedule of thalidomide and lenalidomide may result in better tolerability by decreasing each agent's individual toxicities, while preserving…
- Trial name
- ThRiL (NCT01125176)
- Testing
- thalidomide, lenalidomide, rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Autoimmune Hemolytic Disease (Cold Type) (Warm Type)
A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia
The aim of this prospective study was to evaluate the activity, safety and the duration of the response of low dose rituximab associated with standard oral prednisone as first line therapy in newly diagnosed warm autoimmune…
- Trial name
- NCT01345708
- Testing
- prednisone, low dose rituximab
- Where
- 2 sites in Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Non-Hodgkin's Lymphoma
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is approved by the United States Food and Drug…
- Trial name
- NCT00048555
- Testing
- IDEC-114
- Where
- 22 sites in United States
- Volunteers
- 90 people
- Sponsor
- Biogen
Rheumatoid Arthritis
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan.
- Trial name
- SUNSTONE (NCT00443443)
- Where
- 193 sites in United States, Puerto Rico
- Volunteers
- 1,026 people
- Sponsor
- Genentech, Inc.
Leukemia, Lymphoma
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as bryostatin 1, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00087425
- Testing
- rituximab, bryostatin 1
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute on Aging (NIA)
Lymphoma, Non-Hodgkin
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00347971
- Testing
- recombinant human interleukin 21 and rituximab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- ZymoGenetics
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
The goal of this study is to evaluate the efficacy and safety of a combination of the anti-CD20 monoclonal antibody Rituximab, Dexamethasone, daily high dose Cytarabine twice, and Carboplatin; delivered in an outpatient setting.
- Trial name
- NCT03892421
- Testing
- Rituximab, Carboplatin, Cytarabine Injection
- Where
- Mexico
- Volunteers
- 22 people
- Sponsor
- La Raza Medical Center
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single…
- Trial name
- NCT01557348
- Where
- 215 sites in Canada, Colombia and 10 more
- Volunteers
- 1,239 people
- Sponsor
- Hoffmann-La Roche
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses.
- Trial name
- NCT00168740
- Testing
- rituximab
- Where
- 31 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Biogen
Pemphigus, Auto-immune Thrombocytopenic Purpura
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for various auto-immune diseases.
- Conditions
- Pemphigus, Auto-immune Thrombocytopenic Purpura, Hemolytic Auto-immune Anaemia, Cold Agglutinin Disease
- Trial name
- RITAI (NCT00960713)
- Testing
- Rituximab (MABTHERA® or RITUXAN®).
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Toulouse
Post-transplant Lymphoproliferative Disease (PTLD), Non Burkitt
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Fludarabine may be of benefit to prevent rejection of grafted solid organs in children during chemo-immunotherapy treatment for post transplant lymphoproliferative diseases (PTLDs).
- Trial name
- FCD-R (NCT01088724)
- Testing
- fludarabine, cyclophosphamide, doxorubicin, rituximab
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
This is a pilot study, assessing the feasibility, safety and toxicity of an mTOR (mammalian target of Rapamycin) inhibitor (MTI), rapamycin, when administered with HyperCVAD (Hyperfractionated Cyclophosphamide, Vincristine…
- Conditions
- Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Lymphoblastic Lymphoma
- Trial name
- NCT01184885
- Testing
- Hyper-CVAD, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lymphoma, B Cell
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in…
- Trial name
- NCT00210379
- Testing
- rituximab, CHOP, intrathecal methotrexate
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Lymphoma, Non-Hodgkin
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone…
- Trial name
- NCT02055820
- Testing
- Venetoclax, Cyclophosphamide, Obinutuzumab
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Hoffmann-La Roche
Hematologic Malignancies
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes.
- Trial name
- NCT01810588
- Testing
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 270 people
- Sponsor
- Weill Medical College of Cornell University
Kidney Transplantation
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with…
- Trial name
- NCT00782821
- Testing
- Rabbit Antithymocyte Globulin, Velcade, Rituxan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Multiple Sclerosis
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
The purpose of this study is to evaluate the impact of rapid infusion rituximab on the incidence of infusion-related reactions in patients with Autoimmune Diseases.
- Trial name
- NCT02040116
- Testing
- Rituximab Infusion
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Adult Acute Lymphocytic Leukemia
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients.
- Trial name
- NCT00199004
- Testing
- Cyclophosphamide, Dexamethasone / Prednisolone, Vincristine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
This single arm study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who are receiving methotrexate treatment, and who have had an inadequate response to one anti-TNF alpha therapy.
- Trial name
- NCT00576433
- Testing
- Methotrexate, rituximab [MabThera/Rituxan]
- Where
- 18 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00078949
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 849 people
- Sponsor
- NCIC Clinical Trials Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.